Caplin Steriles receives USFDA approval for Haloperidol Decanoate Injection
Caplin Steriles (Caplin), a Subsidiary Company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Haloperidol Decanoate Injection, 50mg/mL and 100mg/mL Single Dose Vials; 500mg/5mL (100mg/mL) Multiple-Dose Vials, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) HALDOL (haloperidol decanoate) Injection, by Janssen Pharmaceuticals Inc.
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy.
According to IQVIATM (IMS Health), Haloperidol Decanoate Injection had US sales of approximately $16.4 million for the 12 month period ending March 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
4 days ago
- Business Standard
Gland Pharma receives USFDA approval for Angiotensin II Acetate Injection 2.5 mg/mL
Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Angiotensin II Acetate Injection 2.5 mg/mL. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), GIAPREZA of La Jolla Pharma LLC. This Product is indicated for increasing the blood pressure in adults with septic or other distributive shock. Gland Pharma is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity. According to IQVIA, the product had US sales of approximately USD 58 million for the twelve months ending March 2025.
Business Standard
15-05-2025
- Business Standard
Caplin Point Laboratories consolidated net profit rises 17.25% in the March 2025 quarter
Sales rise 10.86% to Rs 502.45 crore Net profit of Caplin Point Laboratories rose 17.25% to Rs 142.57 crore in the quarter ended March 2025 as against Rs 121.59 crore during the previous quarter ended March 2024. Sales rose 10.86% to Rs 502.45 crore in the quarter ended March 2025 as against Rs 453.22 crore during the previous quarter ended March 2024. For the full year,net profit rose 17.33% to Rs 536.31 crore in the year ended March 2025 as against Rs 457.09 crore during the previous year ended March 2024. Sales rose 14.37% to Rs 1937.47 crore in the year ended March 2025 as against Rs 1694.10 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 502.45453.22 11 1937.471694.10 14 OPM % 33.4532.04 - 33.3932.55 - PBDT 193.71162.43 19 742.74617.87 20 PBT 176.67146.03 21 676.78564.43 20 NP 142.57121.59 17 536.31457.09 17
Business Standard
15-05-2025
- Business Standard
Alembic Pharmaceuticals receives USFDA approval for Rivaroxaban Tablets
Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Xarelto Tablets, 2.5 mg, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals, Inc. (Janssen). Rivaroxaban tablets, 2.5mg, are indicated: i) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD), ii) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD. Refer label for a detailed indication. According to IQVIA, Rivaroxaban Tablets USP, 2.5 mg, has an estimated market size of US$ 445 million for twelve months ending March 2025 and Alembic will be launching this strength in Q1FY26. The estimated market size for remaining strengths of Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg, is US$ 8,052 million for twelve months ending March 2025 according to IQVIA.
